The conversation with Stephen Hahn, MD, addressed challenges associated with hydroxychloroquine access during the COVID-19 public health emergency and handling patient concerns about potential cardiac side effects.
High-resolution computed tomography shows evidence of ILD.
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
Lenabasum for Diffuse Cutaneous Systemic Sclerosis
In a new study, Spiera et al. assessed the safety and efficacy of lenabasum, a synthetic, orally administered agonist of cannabinoid receptor 2 that modulates the endocannabinoid system to activate the resolution phase of innate immune responses, in diffuse cutaneous systemic sclerosis…
RheumPAC Supports Rheumatology Through the Pandemic
With usual in-person fundraisers and meetings not possible during the pandemic, RheumPAC is finding creative ways to keep advocating for influential legislation and ensure rheumatology’s voice is heard in Washington, D.C.
The ACR Is Helping Rheumatology Practices Meet COVID-19 Challenges
These are difficult times for rheumatologists. We have seen sharp declines in face-to-face patient visits since the COVID‑19 pandemic began. Many of us have questions about the best ways to maintain employee and patient safety while keeping our practices afloat and continuing to provide optimal care. The volunteer leaders at the ACR continue to care…
The Half-Life of the Truth
My fellow was laughing at me. By itself, I don’t think this was an unusual occurrence. I am quite certain that my fellows laugh at me all the time. That said, when such laughter is called for, I am accustomed to a certain protocol being observed. In general, I expect the laughter to be contained,…
Some Drug Trials Resume after Declines During Pandemic
(Reuters)—Pharmaceutical companies have ramped up clinical trials in the past month, rebounding from a steep decline in activity following the start of the COVID-19 outbreak, though activity remains below pre-pandemic levels, according to new research shareS with Reuters. The research, which was prepared by clinical trial consulting firm Medidata, shows that new subjects entered trials…
Joint Letter to CMS Advocates Against Adding Stelara to Self-Administered Drug List
The ACR, CSRO and Arthritis Foundation asked the Centers for Medicare & Medicaid Services to review the decision to add Stelara to the Self-Administered Drugs list, which would limit access for patients who can’t self-administer.
Biosimilar Prescribing Habits in the VA & Academic Settings
In a new study, Baker et al. examined reference product and biosimilar orders, comparing data from a Veterans Affairs Medical Center (VAMC) to those from an academic medical center…
Research Beyond COVID-19: Collateral Damage
COVID-19 has generated an outpouring of fast-paced, late-breaking new developments. The majority of countries (188) around the world have reported cases of COVID-19.1 As of April 1, 2020, the Centers for Disease Control and Prevention had reported cases in every U.S. jurisdiction (50 states, District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands and…
More Money, More Research: Foundation Report Sheds Light on Funding Gaps
The ACR and Rheumatology Research Foundation hope a new report on rheumatic disease research can leverage more money for ACR members, funding future research…
- « Previous Page
- 1
- …
- 61
- 62
- 63
- 64
- 65
- …
- 249
- Next Page »